These cytokines are very high in plasma of patients with CKM; therefore, through the reduction of inflammatory signaling, sGC activators help to prevent the downstream effects of chronic inflammation, such as endothelial damage, fibrosis, and organ dysfunction, which are particularly concerning in cancer patients with pre-existing cardiovascular or renal conditions [170]. Here, CKM is linked to cancer.